• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    U.S. Physical Therapy Reports First Quarter 2025 Results

    5/7/25 4:24:00 PM ET
    $USPH
    Medical/Nursing Services
    Health Care
    Get the next $USPH alert in real time by email

    Reports Record First Quarter Patient Volume

    U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the first quarter ended March 31, 2025.

    FINANCIAL HIGHLIGHTS

    • Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles ("GAAP") measure, was $19.5 million for the three months ended March 31, 2025 ("2025 First Quarter"), an increase of $2.8 million, or 16.5%, from $16.8 million in the three months ended March 31, 2024 ("2024 First Quarter") primarily driven by acquisitions since the prior year period and an increase in net patient revenue per visit.
    • Net income attributable to USPH's shareholders ("USPH Net Income"), a GAAP measure, was $9.9 million for the 2025 First Quarter compared to $8.0 million in the 2024 First Quarter. In accordance with GAAP, the revaluation of noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings. However, this change is included in the computation of earnings per share. Earnings per share was $0.80 for the 2025 First Quarter compared to $0.46 for the 2024 First Quarter.
    • Operating Results (1), a non-GAAP measure, was $7.3 million in the 2025 First Quarter compared to $7.7 million in the 2024 First Quarter. On a per share basis, Operating Results was $0.48 in the 2025 First Quarter compared to $0.51 in the 2024 First Quarter.
    • Total revenue from physical therapy operations for the 2025 First Quarter increased $22.0 million, or 16.4%, to $156.4 million.
    • Net rate per patient visit for the 2025 First Quarter was $105.66, increasing $2.29 per visit from $103.37 for the 2024 First Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Net rate per patient visit also increased sequentially by $0.93 from $104.73 for the three months ended December 31, 2024. The increase in net rate per patient visit reflects the Company's strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors as well as growing workers compensation as a percent of the Company's overall mix of business.
    • Average daily patient visits per clinic was an all-time first quarter high of 31.4 for the 2025 First Quarter compared to 29.5 in the 2024 First Quarter. Total patient visits were 1,443,805 in the 2025 First Quarter, a 13.9% increase from the 2024 First Quarter.
    • Industrial injury prevention services ("IIP") revenue was $27.4 million for the 2025 First Quarter, an increase of 28.8% as compared to the 2024 First Quarter. IIP gross profit was $5.6 million in the 2025 First Quarter, an increase of $1.3 million, or 29.1%, from $4.3 million in the 2024 First Quarter.
    • During the 2025 First Quarter, the Company added 14 clinics and closed seven clinics bringing its total owned and/or managed clinic count to 773 as of March 31, 2025, compared to 720 as of March 31, 2024.
    • On February 28, 2025, the Company acquired a 65% equity interest in a three-clinic practice with the practice owners retaining a 35% equity interest. The business currently generates $4.3 million in annual revenue and 23,000 in annual visits.
    • On April 30, 2025, the Company announced the acquisition of an outpatient home care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. The practice currently generates approximately $2.1 million in annual revenue.
    • The Company's Board of Directors declared a quarterly dividend of $0.45 per share payable on June 13, 2025, to shareholders of record on May 23, 2025.

    ___________________________

    (1)

    These are non-GAAP Measures. See pages 11 to 13 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure.

    MANAGEMENT'S COMMENTS

    Chris Reading, Chief Executive Officer, said, "Despite our weather-impacted start, we had strong referral and visit demand which accelerated nicely as the quarter progressed. Importantly, our insurance renegotiations and workers compensation efforts are giving us a lift as we enter one of the busiest seasonal periods of the year. While we have more work to do, we are encouraged by our start and committed to further progress."

    2025 First Quarter Versus 2024 First Quarter

    Additional supplemental tables of financial and performance metrics are presented on page 14 of this release.

    Physical Therapy Operations

    Three Months Ended

     

    Variance

     

    March 31, 2025

     

    March 31, 2024

     

    $

     

    %

     

    (In thousands, except percentages)

     

     

     

     

     

    Revenue related to:

     

     

     

     

     

     

     

     

    Mature Clinics (1)

    $

    126,620

     

    $

    128,501

     

    $

    (1,881

    )

    (1.5

    )%

    Clinic additions (2)

     

    25,667

     

     

    44

     

     

    25,623

     

    *

    (7)

    Clinics sold or closed (3)

     

    260

     

     

    2,530

     

     

    (2,270

    )

    *

    (7)

    Net patient revenue

     

    152,547

     

     

    131,075

     

     

    21,472

     

    16.4

    %

    Other (4)

     

    3,861

     

     

    3,350

     

     

    511

     

    15.3

    %

    Total

     

    156,408

     

     

    134,425

     

     

    21,983

     

    16.4

    %

    Operating costs (5)

     

    130,940

     

     

    110,361

     

     

    20,579

     

    18.6

    %

    Gross profit

    $

    25,468

     

    $

    24,064

     

    $

    1,404

     

    5.8

    %

    Financial and operating metrics (not in thousands):

    Net rate per patient visit (1)

    $

    105.66

     

    $

    103.37

     

    $

    2.29

     

    2.2

    %

    Patient visits (1)

     

    1,443,805

     

     

    1,268,002

     

     

    175,803

     

    13.9

    %

    Average daily visits per clinic (1)

     

    31.4

     

     

    29.5

     

     

    1.9

     

    6.4

    %

    Gross margin

     

    16.3

    %

     

    17.9

    %

    Salaries and related costs per visit, clinics (6)

    $

    63.53

     

    $

    61.42

     

    $

    2.11

     

    3.4

    %

    Operating costs per visit, clinics (6)

    $

    89.28

     

    $

    85.50

     

    $

    3.78

     

    4.4

    %

     

    (1) See Glossary of Terms - Revenue Metrics for definition.

    (2) Includes 14 clinics added during the 2025 First Quarter and 103 added during the year ended December 31, 2024.

    (3) Includes 7 clinics closed during the 2025 First Quarter and 45 clinics closed during the year ended December 31, 2024.

    (4) Includes revenues from management contracts.

    (5) Includes costs from management contracts.

    (6) Excludes costs from management contracts and $0.1 million of certain incentive costs related to the Metro acquisition. Please refer to the reconciliation of non-GAAP measures to the most directly comparable GAAP measure on page 13.

    (7) Not meaningful.

     

    Net revenue from physical therapy operations increased $22.0 million, or 16.4%, to $156.4 million for the 2025 First Quarter from $134.4 million for the 2024 First Quarter. This increase was due to the increase in visits from the 53 net clinics added since the comparable prior year period and an increase in net rate per patient visit, which reflects the Company's strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors as well as growing workers compensation as a percent of the Company's overall mix of business. Net rate per patient visit for the 2025 First Quarter was $105.66, increasing $2.29 per visit from $103.37 for the 2024 First Quarter, despite the approximate 2.9% Medicare rate reduction which went into effect on January 1, 2025. Net rate per patient visit also increased sequentially by $0.93 from $104.73 for the three months ended December 31, 2024.

    Operating costs from physical therapy operations increased $20.6 million, or 18.6%, to $130.9 million in the 2025 First Quarter from $110.4 million in the 2024 First Quarter primarily driven by the 53 net clinics added since the comparable prior year period. Salaries and related costs per visit was $63.53 in the 2025 First Quarter compared to $61.42 in the 2024 First Quarter while total operating costs per visit was $89.28 compared to $85.50 over the same periods, respectively.

    Gross profit from physical therapy operations in the 2025 First Quarter was $25.5 million with a gross profit margin of 16.3% compared to $24.1 million with a gross profit margin of 17.9% in the 2024 First Quarter.

    Industrial Injury Prevention Services

    Three Months Ended

     

    Variance

    March 31, 2025

     

    March 31, 2024

     

    $

     

    %

    (In thousands, except percentages)

    Net revenue

    $

    27,380

     

    $

    21,250

     

    $

    6,130

    28.8

    %

    Operating costs

     

    21,783

     

     

    16,913

     

     

    4,870

    28.8

    %

    Gross profit

    $

    5,597

     

    $

    4,337

     

    $

    1,260

    29.1

    %

     

    Gross margin

     

    20.4

    %

     

    20.4

    %

     

     

    IIP revenue increased $6.1 million, or 28.8%, to $27.4 million for the 2025 First Quarter as compared to $21.3 million for the 2024 First Quarter. Gross profit from IIP operations in the 2025 First Quarter increased $1.3 million, or 29.1%, to $5.6 million from $4.3 million in the 2024 First Quarter. The gross profit margin from IIP operations was 20.4% in each of the 2025 First Quarter and 2024 First Quarter. Excluding the IIP acquisition made in April 2024, IIP revenue increased by $3.2 million or 15.1% in the 2025 First Quarter and gross profit increased $0.6 million or 13.1% in the 2025 First Quarter over the comparable prior year period.

    Corporate Office and Other Expenses

    Corporate office costs increased to $16.2 million in the 2025 First Quarter from $14.1 million in the 2024 First Quarter. This increase was primarily to support the larger number of clinics as well as expenses related to the integration of the Company's recent acquisitions. As a ratio to net revenue, corporate office costs improved to 8.8% in the 2025 First Quarter compared to 9.0% in the 2024 Fourth Quarter.

    The Company revalued contingent consideration related to certain acquisitions and recognized a net non-cash gain (a decrease in the related liabilities) of $4.8 million in the 2025 First Quarter compared to $0.6 million in the 2024 First Quarter.

    Operating income was $19.6 million for the 2025 First Quarter compared to $14.9 million for the 2024 First Quarter, an increase of 31.6% over the comparable period.

    Interest expense increased by $0.3 million to $2.3 million for the 2025 First Quarter compared to $2.0 million in the 2024 First Quarter due to a higher average outstanding balance on our revolving credit facility in the 2025 First Quarter. The interest rate associated with borrowings on the Company's credit facility was 4.9% for the 2025 First Quarter and 4.7% for the 2024 First Quarter, with an all-in effective interest rate, including all associated costs of 5.5% and 5.3% over the same periods, respectively.

    Interest income was less than $0.1 million during the 2025 First Quarter compared to $1.5 million in the 2024 First Quarter as the cash on the balance sheet at the end of the 2024 First Quarter has been deployed into acquisitions since that time.

    The Company revalued a put-right liability related to the future purchase of an IIP business and recognized a net non-cash expense (an increase in the related liability) of $0.4 million in the 2025 First Quarter compared to $0.1 million in the 2024 First Quarter.

    The provision for income taxes was $3.9 million in the 2025 First Quarter compared to $3.1 million during the 2024 First Quarter while the effective tax rate was 28.1% in each of the same periods, respectively.

    USPH Net Income and Non-GAAP Measures

    Net income attributable to non-controlling interest (temporary and permanent) was $3.6 million in both the 2025 First Quarter and the 2024 First Quarter.

    USPH Net Income was $9.9 million for the 2025 First Quarter compared to $8.0 million in the 2024 First Quarter. In accordance with GAAP, the revaluation of redeemable noncontrolling interest, net of taxes, is not included in net income but is charged directly to retained earnings; however, this change is included in the computation of earnings per share. Earnings per share was $0.80 for the 2025 First Quarter compared to $0.46 for the 2024 First Quarter.

    Non-GAAP Adjusted EBITDA (1) was $19.5 million for the 2025 First Quarter, an increase of $2.8 million or 16.5%, from $16.8 million for the 2024 First Quarter. Non-GAAP Operating Results (1) was $7.3 million, or $0.48 per share, in the 2025 First Quarter compared to $7.7 million, or $0.51 per share, in the 2024 First Quarter.

    ___________________________

    (1)

    These are Non-GAAP Measures. See pages 11 to 12 of this release for the definition and reconciliation of Adjusted EBITDA and Operating Results measures to the most directly comparable GAAP measure.

    BALANCE SHEET AND CASH FLOW

    Total cash and cash equivalents were $39.2 million as of March 31, 2025, compared to $41.4 million as of December 31, 2024, and $132.3 million as of March 31, 2024. The Company had $164.9 million in outstanding borrowings and $147.0 million in available credit under its credit facilities as of March 31, 2025. This compares to $151.6 million of outstanding borrowings and $164.0 million in available credit under its credit facilities as of December 31, 2024.

    RECENT ACQUISITIONS

    On February 28, 2025, the Company acquired a 65% equity interest in a three-clinic practice with the original practice owners retaining 35% equity interest. The business currently generates $4.3 million in annual revenue and 23,000 in annual visits.

    On April 30, 2025, the Company announced the acquisition of an outpatient home care physical and speech therapy practice through its 50%-owned subsidiary, MSO Metro, LLC. The practice currently generates approximately $2.1 million in annual revenue.

    The Company's strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.

    QUARTERLY DIVIDEND

    The Company's Board of Directors declared a quarterly dividend of $0.45 per share payable on June 13, 2025, to shareholders of record on May 23, 2025.

    CONFERENCE CALL INFORMATION

    U.S. Physical Therapy's management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on May 8, 2025, to discuss the Company's financial results for the first quarter ended March 31, 2025. Interested parties may participate in the call by dialing (800) 274-8461 (Primary) or (203) 518-9814 (Alternate) and conference ID of USPHQ125. Please call approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until August 7, 2025, on the Company's website.

    FORWARD LOOKING STATEMENTS

    This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as "believes," "expects," "intends," "plans," "appear," "should" and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

    • changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
    • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
    • changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
    • private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
    • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
    • compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply;
    • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
    • the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
    • certain of our acquisition agreements contain put-rights related to a future purchase of significant equity interests in our subsidiaries or in a separate company;
    • the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
    • our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
    • changes as the result of government enacted national healthcare reform;
    • the ability to control variable interest entities for which we do not have a direct ownership;
    • business and regulatory conditions including federal and state regulations;
    • governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
    • revenue and earnings expectations;
    • contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results;
    • legal actions, which could subject us to increased operating costs and uninsured liabilities;
    • general economic conditions, including but not limited to inflationary and recessionary periods;
    • actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations;
    • our business depends on hiring, training, and retaining qualified employees;
    • availability and cost of qualified physical therapists;
    • competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
    • our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
    • impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
    • maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
    • a security breach of our or our third party vendors' information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
    • maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
    • maintaining adequate internal controls;
    • maintaining necessary insurance coverage;
    • availability, terms, and use of capital; and
    • weather and other seasonal factors.

    Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on March 3, 3025 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.

    GLOSSARY OF TERMS – REVENUE METRICS

    Mature clinics are clinics opened or acquired prior to January 1, 2024, and are still operating as of the balance sheet date.

    Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.

    Patient visits is the number of unique patient visits during the periods presented.

    Average daily visits per clinic is patient visits divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.

    ABOUT U.S. PHYSICAL THERAPY, INC.

    Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 773 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

    More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

     
     
     

    U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

    (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
     

     

    Three Months Ended

    March 31, 2025

     

    March 31, 2024

     

    Net patient revenue

    $

    152,547

     

    $

    131,075

     

    Other revenue

     

    31,241

     

     

    24,600

     

    Net revenue

     

    183,788

     

     

    155,675

     

    Operating cost

    Salaries and related costs

     

    111,249

     

     

    93,731

     

    Rent, supplies, contract labor and other

     

    33,844

     

     

    27,904

     

    Depreciation and amortization

     

    5,540

     

     

    3,885

     

    Provision for credit losses

     

    1,848

     

     

    1,627

     

    Clinic closure costs - lease and other

     

    242

     

     

    127

     

    Total operating cost

     

    152,723

     

     

    127,274

     

     

     

     

     

     

    Gross profit

     

    31,065

     

     

    28,401

     

     

     

     

     

     

    Corporate office costs

     

    16,245

     

     

    14,085

     

    Gain on change in fair value of contingent earn-out consideration

     

    (4,822

    )

     

    (612

    )

    Operating income

     

    19,642

     

     

    14,928

     

     

     

     

     

     

    Other (expense) income

    Interest expense, debt and other

     

    (2,279

    )

     

    (1,968

    )

    Interest income from investments

     

    24

     

     

    1,543

     

    Change in revaluation of put-right liability

     

    (404

    )

     

    (80

    )

    Equity in earnings of unconsolidated affiliate

     

    393

     

     

    271

     

    Loss on sale of a partnership

     

    (123

    )

     

    -

     

    Other

     

    75

     

     

    62

     

    Total other expense

     

    (2,314

    )

     

    (172

    )

    Income before taxes

     

    17,328

     

     

    14,756

     

     

    Provision for income taxes

     

    3,860

     

     

    3,139

     

    Net income

     

    13,468

     

     

    11,617

     

     

     

     

     

     

     

     

     

     

    Less: Net income attributable to non-controlling interest

    Redeemable non-controlling interest - temporary equity

     

    (2,012

    )

     

    (2,227

    )

    Non-controlling interest - permanent equity

     

    (1,557

    )

     

    (1,344

    )

     

    (3,569

    )

     

    (3,571

    )

     

    Net income attributable to USPH shareholders

    $

    9,899

     

    $

    8,046

     

     

    Basic and diluted earnings per share attributable to USPH shareholders (1)

    $

    0.80

     

    $

    0.46

     

     

    Shares used in computation - basic and diluted

     

    15,132

     

     

    15,017

     

     

    Dividends declared per common share

    $

    0.45

     

    $

    0.44

     

    (1)

    See page 12 of this press release for the calculation of basic and diluted earnings per share.

     
     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (IN THOUSANDS)
     

     

    Three Months Ended

    March 31, 2025

     

    March 31, 2024

     

    Net income

    $

    13,468

     

    $

    11,617

     

    Other comprehensive gain:

    Unrealized (loss) gain on cash flow hedge

     

    (1,331

    )

     

    1,781

     

    Tax effect at statutory rate (federal and state)

     

    340

     

     

    (455

    )

    Comprehensive income

    $

    12,477

     

    $

    12,943

     

    Comprehensive income attributable to non-controlling interest

     

    (3,569

    )

     

    (3,571

    )

    Comprehensive income attributable to USPH shareholders

    $

    8,908

     

    $

    9,372

     

     
     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEET

    (IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
     

     

    March 31, 2025

     

    December 31, 2024

    (unaudited)

     

     

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    39,183

     

    $

    41,362

     

    Patient accounts receivable, less provision for credit losses of $3,620 and $3,506, respectively

     

    64,760

     

     

    59,040

     

    Accounts receivable - other

     

    26,136

     

     

    26,626

     

    Other current assets

     

    15,274

     

     

    10,555

     

    Total current assets

     

    145,353

     

     

    137,583

     

     

    Fixed assets:

    Furniture and equipment

     

    68,802

     

     

    68,128

     

    Leasehold improvements

     

    53,504

     

     

    51,105

     

    Fixed assets, gross

     

    122,306

     

     

    119,233

     

    Less accumulated depreciation and amortization

     

    (89,542

    )

     

    (87,093

    )

    Fixed assets, net

     

    32,764

     

     

    32,140

     

    Operating lease right-of-use assets

     

    133,197

     

     

    133,936

     

    Investment in unconsolidated affiliate

     

    12,273

     

     

    12,190

     

    Goodwill

     

    674,387

     

     

    667,152

     

    Other identifiable intangible assets, net

     

    177,328

     

     

    179,311

     

    Other assets

     

    4,385

     

     

    5,155

     

    Total assets

    $

    1,179,687

     

    $

    1,167,467

     

     

     

     

    LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTEREST

     

     

    Current liabilities:

     

     

    Accounts payable - trade

    $

    6,088

     

    $

    5,936

     

    Accrued expenses

     

    68,326

     

     

    59,513

     

    Current portion of operating lease liabilities

     

    40,124

     

     

    39,835

     

    Current portion of term loan and notes payable

     

    9,257

     

     

    10,999

     

    Total current liabilities

     

    123,795

     

     

    116,283

     

    Notes payable, net of current portion

     

    387

     

     

    903

     

    Revolving facility

     

    28,000

     

     

    11,000

     

    Term loan, net of current portion and deferred financing costs

     

    128,851

     

     

    130,627

     

    Deferred taxes

     

    34,055

     

     

    29,465

     

    Operating lease liabilities, net of current portion

     

    100,688

     

     

    101,868

     

    Other long-term liabilities

     

    4,903

     

     

    18,275

     

    Total liabilities

     

    420,679

     

     

    408,421

     

     

    Redeemable non-controlling interest - temporary equity

     

    260,047

     

     

    269,025

     

     

    Commitments and Contingencies

     

    U.S. Physical Therapy, Inc. ("USPH") shareholders' equity:

    Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding

     

    -

     

     

    -

     

    Common stock, $.01 par value, 20,000,000 shares authorized, 17,406,426 and 17,309,120 shares issued, respectively

     

    172

     

     

    172

     

    Additional paid-in capital

     

    292,773

     

     

    290,321

     

    Accumulated other comprehensive gain

     

    1,783

     

     

    2,799

     

    Retained earnings

     

    234,161

     

     

    227,265

     

    Treasury stock at cost, 2,214,737 shares

     

    (31,628

    )

     

    (31,628

    )

    Total USPH shareholders' equity

     

    497,261

     

     

    488,929

     

    Non-controlling interest - permanent equity

     

    1,700

     

     

    1,092

     

    Total USPH shareholders' equity and non-controlling interest - permanent equity

     

    498,961

     

     

    490,021

     

    Total liabilities, redeemable non-controlling interest,

    USPH shareholders' equity and non-controlling interest - permanent equity

    $

    1,179,687

     

    $

    1,167,467

     

     
     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (IN THOUSANDS)
     

     

    Three Months Ended

    March 31, 2025

    March 31, 2024

    OPERATING ACTIVITIES

    Net income including non-controlling interest

    $

    13,468

     

    $

    11,617

     

    Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:

    Depreciation and amortization

     

    5,867

     

     

    4,095

     

    Provision for credit losses

     

    1,848

     

     

    1,627

     

    Equity-based awards compensation expense

     

    1,771

     

     

    1,997

     

    Amortization of debt issue costs

     

    106

     

     

    106

     

    Change in deferred income taxes

     

    5,242

     

     

    1,943

     

    Change in revaluation of put-right liability

     

    404

     

     

    80

     

    Gain on change in fair value of contingent earn-out consideration

     

    (4,822

    )

     

    (612

    )

    Equity of earnings in unconsolidated affiliate

     

    (393

    )

     

    (271

    )

    Loss on sale of fixed assets

     

    -

     

     

    5

     

    Loss on sale of a partnership

     

    123

     

     

    -

     

    Changes in operating assets and liabilities:

    Increase in patient accounts receivable

     

    (7,341

    )

     

    (5,124

    )

    Decrease (increase) in accounts receivable - other

     

    774

     

     

    (3,985

    )

    Increase in other current and long term assets

     

    (6,209

    )

     

    (433

    )

    Decrease in accounts payable and accrued expenses

     

    (14,229

    )

     

    (6,678

    )

    (Decrease) increase in long term liabilities

     

    (1,284

    )

     

    52

     

    Net cash (used in) provided by operating activities

     

    (4,675

    )

     

    4,419

     

     

    INVESTING ACTIVITIES

    Purchase of fixed assets

     

    (2,579

    )

     

    (1,838

    )

    Purchase of majority interest in businesses, net of cash acquired

     

    (4,211

    )

     

    (15,971

    )

    Purchase of redeemable non-controlling interest, temporary equity

     

    (907

    )

     

    (2,702

    )

    Purchase of non-controlling interest, permanent equity

     

    -

     

     

    (498

    )

    Proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity

     

    15

     

     

    67

     

    Proceeds from the sale of non-controlling interest, permanent equity

     

    -

     

     

    23

     

    Proceeds from sale of partnership

     

    700

     

     

    -

     

    Distributions from unconsolidated affiliate

     

    310

     

     

    367

     

    Other

     

    44

     

     

    88

     

    Net cash (used in) investing activities

     

    (6,628

    )

     

    (20,464

    )

     

    FINANCING ACTIVITIES

    Proceeds from revolving facility

     

    17,000

     

     

    -

     

    Distributions to non-controlling interest, permanent and temporary equity

     

    (3,653

    )

     

    (3,160

    )

    Payments on term loan

     

    (3,750

    )

     

    (938

    )

    Principal payments on notes payable

     

    (473

    )

     

    (392

    )

    Net cash provided by (used in) financing activities

     

    9,124

     

     

    (4,490

    )

     

    Net (decrease) in cash and cash equivalents

     

    (2,179

    )

     

    (20,535

    )

    Cash and cash equivalents - beginning of period

     

    41,362

     

     

    152,825

     

    Cash and cash equivalents - end of period

    $

    39,183

     

    $

    132,290

     

     

    SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

    Cash paid during the period for:

    Income taxes

    $

    7,359

     

    $

    367

     

    Interest paid

     

    2,205

     

     

    1,844

     

    Non-cash investing and financing transactions during the period:

    Purchase of businesses - seller financing portion

     

    -

     

     

    500

     

    Purchase of redeemable non-controlling interest, temporary equity, recorded in accrued liabilities

     

    6,672

     

     

    -

     

    Fair market value of initial contingent consideration related to purchase of businesses

     

    1,259

     

     

    -

     

    Notes payable related to purchase of redeemable non-controlling interest, temporary equity

     

    89

     

     

    -

     

    Notes receivable related to sale of redeemable non-controlling interest, temporary equity

     

    646

     

     

    315

     

    Notes receivable related to the sale of non-controlling interest, permanent equity

     

    -

     

     

    243

     

    Offset to notes receivable associated with purchase of redeemable non-controlling interest

     

    180

     

     

    75

     

    Dividends payable to USPH shareholders

     

    6,836

     

     

    6,630

     

     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    ADJUSTED EBITDA AND OPERATING RESULTS

    The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. The tables also provide a reconciliation of additional non-GAAP measures to the most comparable GAAP measure. Management believes providing Adjusted EBITDA and Operating Results to investors is useful for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.

    Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial systems upgrade, loss on sale of a partnership and other income and related portions for non-controlling interests.

    Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less, changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial systems upgrade and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.

    Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE

    (IN THOUSANDS, EXCEPT PER SHARE DATA)
     

     

     

    Three Months Ended

     

    March 31, 2025

     

    March 31, 2024

     

    Adjusted EBITDA (a non-GAAP measure)

    Net income attributable to USPH shareholders

    $

    9,899

     

    $

    8,046

     

    Adjustments:

    Provision for income taxes

     

    3,860

     

     

    3,139

     

    Depreciation and amortization

     

    5,867

     

     

    4,095

     

    Interest expense, debt and other, net

     

    2,279

     

     

    1,968

     

    Interest income from investments

     

    (24

    )

     

    (1,543

    )

    Equity-based awards compensation expense

     

    1,771

     

     

    1,997

     

    Change in revaluation of put-right liability

     

    404

     

     

    80

     

    Change in fair value of contingent earn-out consideration

     

    (4,822

    )

     

    (612

    )

    Clinic closure costs (1)

     

    242

     

     

    126

     

    Business acquisition related costs (2)

     

    480

     

     

    -

     

    ERP implementation costs (3)

     

    62

     

     

    -

     

    Loss on sale of a partnership

     

    123

     

     

    -

     

    Other loss (income)

     

    (75

    )

     

    (62

    )

    Allocation to non-controlling interests

     

    (527

    )

     

    (463

    )

    $

    19,539

     

    $

    16,771

     

     

    Operating Results (a non-GAAP measure)

    Net income attributable to USPH shareholders

    $

    9,899

     

    $

    8,046

     

    Adjustments:

    Change in fair value of contingent earn-out consideration

     

    (4,822

    )

     

    (612

    )

    Change in revaluation of put-right liability

     

    404

     

     

    80

     

    Clinic closure costs (1)

     

    242

     

     

    126

     

    Business acquisition related costs (2)

     

    480

     

     

    -

     

    ERP implementation costs (3)

     

    62

     

     

    -

     

    Loss on sale of a partnership

     

    123

     

     

    -

     

    Allocation to non-controlling interest

     

    (10

    )

     

    (16

    )

    Tax effect at statutory rate (federal and state)

     

    935

     

     

    108

     

    $

    7,313

     

    $

    7,732

     

     
     

    Operating Results per share (a non-GAAP measure)

    $

    0.48

     

    $

    0.51

     

     

    Earnings per share

    Computation of earnings per share - USPH shareholders:

    Net income attributable to USPH shareholders

    $

    9,899

     

    $

    8,046

     

    Charges to retained earnings:

    Revaluation of redeemable non-controlling interest

     

    2,903

     

     

    (1,439

    )

    Tax effect at statutory rate (federal and state)

     

    (742

    )

     

    368

     

    $

    12,060

     

    $

    6,975

     

     

    Earnings per share (basic and diluted)

    $

    0.80

     

    $

    0.46

     

     

    Shares used in computation - basic and diluted

     

    15,132

     

     

    15,017

     

    ___________________________

    (1)

    Costs associated with the closure of seven and six clinics during the 2025 First Quarter and the 2024 First Quarter, respectively.

    (2)

    Primarily consists of legal and consulting expenses related to the acquisitions of equity interests in certain partnerships. 

    (3)

    Consists of costs related to a one-time financial systems upgrade. 

     
     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    RECONCILIATION OF NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES

    (IN THOUSANDS, EXCEPT PER SHARE DATA AND PERCENTAGES)
     

     

    The tables below reconcile other non-GAAP measures to the most directly comparable GAAP measures. 

     

    Three Months Ended

    March 31, 2025

    As Reported

    (GAAP)

     

    Adjustments (1)

     

    As Adjusted

    (Non-GAAP)

    (in thousands, except percentages)

    Segment information - Physical Therapy Operations

    Salaries and related costs, clinics (2)

    $

    91,799

     

    $

    (75

    )

    $

    91,724

     

    Operating costs, clinics (2)

    $

    128,971

     

    $

    (75

    )

    $

    128,896

     

    Gross profit

    $

    25,468

     

    $

    75

     

    $

    25,543

     

    Gross margin

     

    16.3

    %

    *

     

    16.3

    %

    Number of visits

     

    1,443,805

     

     

     

     

     

    1,443,805

     

    Salaries and related costs per visit, clinics

    $

    63.58

     

     

    $

    (0.05

    )

     

    $

    63.53

     

    Operating costs per visit, clinics

    $

    89.33

     

     

    $

    (0.05

    )

     

    $

    89.28

     

    ___________________________

    (1)

    Certain incentive costs related to the Metro acquisition. We believe that presenting this information will allow investors to evaluate the performance of the Company's business more objectively.

    (2)

    Excludes costs related to management contracts. 

    * Not meaningful

     
     
     
     

    U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

    SUPPLEMENTAL FINANCIAL AND PERFORMANCE METRICS
     

     

    Revenue Metrics 

     

    Number of Clinics(2)

     

    Net Rate Per Visit(1)

     

    Visits(1)

     

    Average Visits Per Day(1)

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

    2024

     

    First quarter

    736

    679

    $105.66

    $103.37

    1,443,805

    1,268,002

    31.4

    29.5

    Second quarter

    -

    681

    -

    $105.05

    -

    1,335,335

    -

    30.6

    Third quarter

    -

    661

    -

    $105.65

    -

    1,317,051

    -

    30.1

    Fourth Quarter

    -

    729

    -

    $104.73

    -

    1,432,801

    -

    31.7

    Year

    -

    729

    -

    $104.71

    1,443,805

    5,353,189

    -

    30.4

     
     

    Clinic Count Roll Forward (2) 

     

    Three Months Ended

    March 31, 2025

     

    March 31, 2024

    Number of clinics owned or managed, beginning of period

    729

     

    671

     

    Additions (3)

    14

     

    14

     

    Closed or sold

    (7

    )

    (6

    )

    Number of clinics owned or managed, end of period

    736

    679

     

    ___________________________

    (1)

    See definition of the metrics above in the Glossary of Terms – Revenue Metrics section on page 6.

    (2)

    The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above, as of March 31, 2025, the Company managed 37 clinics bringing the total owned/managed clinics to 773. As of March 31, 2024, the Company managed 41 clinics bringing the total owned/managed clinics to 720. 

    (3)

    Includes clinics added through acquisitions.

     
     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507767612/en/

    U.S. Physical Therapy, Inc.

    Carey Hendrickson, Chief Financial Officer

    email: [email protected]

    Chris Reading, Chief Executive Officer

    (713) 297-7000

    Three Part Advisors

    Joe Noyons

    (817) 778-8424

    Get the next $USPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USPH

    DatePrice TargetRatingAnalyst
    12/16/2024$100.00 → $115.00Neutral → Buy
    BofA Securities
    12/16/2024$113.00Mkt Outperform
    JMP Securities
    10/7/2024$114.00 → $90.00Buy → Neutral
    BofA Securities
    9/22/2023$108.00Overweight
    JP Morgan
    6/30/2023$138.00Buy
    BofA Securities
    12/14/2021$120.00Market Perform → Market Outperform
    CJS Securities
    8/6/2021$130.00 → $139.00Outperform
    Barrington Research
    More analyst ratings

    $USPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gilmartin Kathleen A bought $172,180 worth of shares (2,000 units at $86.09), increasing direct ownership by 12% to 18,904 units (SEC Form 4)

      4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)

      9/3/24 6:38:08 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • Gilmartin Kathleen A bought $82,340 worth of shares (1,000 units at $82.34), increasing direct ownership by 7% to 15,480 units (SEC Form 4)

      4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)

      11/13/23 7:09:28 PM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. Physical Therapy Reports First Quarter 2025 Results

      Reports Record First Quarter Patient Volume U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the first quarter ended March 31, 2025. FINANCIAL HIGHLIGHTS Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles ("GAAP") measure, was $19.5 million for the three months ended March 31, 2025 ("2025 First Quarter"), an increase of $2.8 million, or 16.5%, from $16.8 million in the three months ended March 31, 2024 ("2024 First Quarter") primarily driven by acquisitions since the prior year period and an increase in net patien

      5/7/25 4:24:00 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy Announces the Acquisition of an Outpatient Home Care Physical and Speech Therapy Practice

      U.S. Physical Therapy, Inc. (the Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of an outpatient home care practice that provides physical, occupational, and speech therapy through its 50%-owned subsidiary, MSO Metro, LLC ("Metro"). The practice currently generates approximately $2.1 million in annual revenues. Metro acquired an 80% interest in the acquired company with the current owners retaining a 20% ownership interest. Eric Williams, President and Chief Operating Officer-East, said, "We are extremely excited to further extend our outpatient reach with the ability to now

      4/30/25 4:05:00 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call Dates

      U.S. Physical Therapy, Inc. (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, May 8, 2025. Conference Call Date: Thursday, May 8, 2025     Time: 10:30 am Eastern /9:30 am Central   Dial-In Number: (800) 274-8461 Primary or     (203) 518-9814 Alternate   Conference ID: USPHQ125   (In order to join this conference call, you will be require

      4/23/25 8:30:00 AM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Financials

    Live finance-specific insights

    See more
    • U.S. Physical Therapy Reports First Quarter 2025 Results

      Reports Record First Quarter Patient Volume U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the first quarter ended March 31, 2025. FINANCIAL HIGHLIGHTS Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles ("GAAP") measure, was $19.5 million for the three months ended March 31, 2025 ("2025 First Quarter"), an increase of $2.8 million, or 16.5%, from $16.8 million in the three months ended March 31, 2024 ("2024 First Quarter") primarily driven by acquisitions since the prior year period and an increase in net patien

      5/7/25 4:24:00 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy Announces the Acquisition of an Outpatient Home Care Physical and Speech Therapy Practice

      U.S. Physical Therapy, Inc. (the Company") (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of an outpatient home care practice that provides physical, occupational, and speech therapy through its 50%-owned subsidiary, MSO Metro, LLC ("Metro"). The practice currently generates approximately $2.1 million in annual revenues. Metro acquired an 80% interest in the acquired company with the current owners retaining a 20% ownership interest. Eric Williams, President and Chief Operating Officer-East, said, "We are extremely excited to further extend our outpatient reach with the ability to now

      4/30/25 4:05:00 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call Dates

      U.S. Physical Therapy, Inc. (NYSE:USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, May 8, 2025. Conference Call Date: Thursday, May 8, 2025     Time: 10:30 am Eastern /9:30 am Central   Dial-In Number: (800) 274-8461 Primary or     (203) 518-9814 Alternate   Conference ID: USPHQ125   (In order to join this conference call, you will be require

      4/23/25 8:30:00 AM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by U.S. Physical Therapy Inc.

      SC 13G/A - U S PHYSICAL THERAPY INC /NV (0000885978) (Subject)

      11/13/24 4:05:19 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by U.S. Physical Therapy Inc.

      SC 13G - U S PHYSICAL THERAPY INC /NV (0000885978) (Subject)

      10/22/24 3:57:52 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by U.S. Physical Therapy Inc.

      SC 13G - U S PHYSICAL THERAPY INC /NV (0000885978) (Subject)

      2/14/24 10:04:34 AM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hendrickson Carey P gifted 63 shares, decreasing direct ownership by 0.22% to 28,506 units (SEC Form 4)

      4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)

      3/18/25 9:00:04 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • COO Reeve Graham D. sold $142,050 worth of shares (1,730 units at $82.11) (SEC Form 4)

      4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)

      3/7/25 8:30:06 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • Chairman of the Board and CEO Reading Christopher J was granted 20,250 shares, increasing direct ownership by 21% to 116,088 units (SEC Form 4)

      4 - U S PHYSICAL THERAPY INC /NV (0000885978) (Issuer)

      2/26/25 8:00:07 PM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board

      EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB). "I am very pleased to welcome Dr. Harris to our new Business Advisory Board," said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. "As we continue

      6/20/23 8:00:00 AM ET
      $POAI
      $RTX
      $USPH
      Industrial Specialties
      Health Care
      Aerospace
      Industrials
    • National Kidney Foundation Appoints Anne Motsenbocker to Board of Directors

      ~Highly Esteemed Growth Strategist and Financial Expert with Decades of Business Acumen~ NEW YORK, Oct. 18, 2022 /PRNewswire/ -- The National Kidney Foundation (NKF) is pleased to announce the appointment of Anne Motsenbocker to its national Board of Directors. We're honored & excited Anne has joined the national board to share her extensive business acumen in board governance.Motsenbocker resides in Dallas, Texas and is a former banker and seasoned board member bringing over 35 years of commercial banking and wealth management expertise due to the numerous roles she held at J

      10/18/22 9:00:00 AM ET
      $CSWI
      $USPH
      Home Furnishings
      Industrials
      Medical/Nursing Services
      Health Care
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JON BATES AS ITS NEW CHIEF FINANCIAL OFFICER

      HOUSTON, June 10, 2022 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, today announced the appointment of Jon Bates as the Company's Chief Financial Officer effective on or about June 30, 2022. On May 3, 2022, Michael Bowen notified the company that he intends to retire as Chief Financial Officer of the Company. In connection with Mr. Bowen's retirement, the Company's Board formed a search committee.  On June 8, 2022, the Company announced the appointme

      6/10/22 6:00:00 AM ET
      $NUTX
      $USPH
      Business Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $USPH
    SEC Filings

    See more
    • SEC Form 10-Q filed by U.S. Physical Therapy Inc.

      10-Q - U S PHYSICAL THERAPY INC /NV (0000885978) (Filer)

      5/9/25 4:05:54 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - U S PHYSICAL THERAPY INC /NV (0000885978) (Filer)

      5/7/25 5:01:34 PM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - U S PHYSICAL THERAPY INC /NV (0000885978) (Filer)

      4/30/25 4:11:41 PM ET
      $USPH
      Medical/Nursing Services
      Health Care

    $USPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • U.S. Physical Therapy upgraded by BofA Securities with a new price target

      BofA Securities upgraded U.S. Physical Therapy from Neutral to Buy and set a new price target of $115.00 from $100.00 previously

      12/16/24 6:45:03 AM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • JMP Securities initiated coverage on U.S. Physical Therapy with a new price target

      JMP Securities initiated coverage of U.S. Physical Therapy with a rating of Mkt Outperform and set a new price target of $113.00

      12/16/24 6:39:42 AM ET
      $USPH
      Medical/Nursing Services
      Health Care
    • U.S. Physical Therapy downgraded by BofA Securities with a new price target

      BofA Securities downgraded U.S. Physical Therapy from Buy to Neutral and set a new price target of $90.00 from $114.00 previously

      10/7/24 8:26:44 AM ET
      $USPH
      Medical/Nursing Services
      Health Care